MET and lung adenocarcinoma: In at least two out of these four cases (KIF5B–MET in lung adenocarcinoma and TFG–MET in thyroid papillary carcinoma), the predicted chimeric protein follows the classic activation paradigm, fusing dimerization motifs to an intact kinase domain.